Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06136546 · ClinicalTrials.gov registry record · Phase 2
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
A Phase 2 study of Inflammation and Depressive Disorder, Major, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06136546 is a Phase 2 study of Inflammation and Depressive Disorder, Major that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06136546, a Phase 2 study of Inflammation and Depressive Disorder, Major, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Infliximab
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2029-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06136546
The ClinicalTrials.gov registry entry for NCT06136546 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 287-participant average among 132 other Inflammation trials with a reported enrollment target (65% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06136546 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06136546 about?
NCT06136546 is a clinical study titled "Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab". This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.
What is the current status of trial NCT06136546?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-01-23. Estimated completion is 2029-01-31.
What conditions does trial NCT06136546 study?
This clinical trial studies the following conditions: Inflammation, Depressive Disorder, Major.
What interventions are being tested in trial NCT06136546?
The interventions under investigation include: Placebo (OTHER), Infliximab (DRUG).
Who is sponsoring clinical trial NCT06136546?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06136546 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
-
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Modulating Exercise Dosage to Improve Concussion Recovery
RECRUITING · Phase 2
-
Passive Stretching in Peripheral Arterial Disease Patients
RECRUITING · Phase 2
-
Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.